Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
Salles, Gilles , Schuster, Stephen J. , Dreyling, Martin , Fischer, Luca , Patten, Piers , Smith, Sonali M. , Ubieto, Ana Jiménez , Davis, Keith L. , Anjos, Caroline Oliveira dos , Chu, Jufen, Zhang, Jie , Bodoni, Chiara Lobetti, Thiéblemont, Catherine , Fowler, Nathan , Martínez‐López, Joaquín , Link, Brian K. , Martinez-Lopez, Joaquin , Patten, Piers E M , Smith, Sonali M , Dickinson, Michael , Wang, Yucai , Link, Brian K , Martinez-Lopez, Joaquin , Salles, Gilles A , Dreyling, Martin , Martinez-Lopez, Joaquin , Schuster, Stephen J , Kuruvilla, John , Tresckow, Bastian von , Dickinson, Michael , Wang, Yucai

Mayo Clinic

Blood Advances | August 16, 2022 | Volume: 6 | Issue: 22 | Pages: 5835-5843

10.1182/bloodadvances.2022008150 | PMID 35973192 Get It

Abstract The ELARA trial indicates tisagenlecleucel (tisa-cel) is an effective anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory follicular lymphoma (r/r FL). As ELARA is a single-arm trial, this study compares tisa-cel outcomes from the ELARA trial with usual care from a real-world cohort. ELARA enrolled 98 patients as of 29 March 2021 (median follow-up: 15 months from enrollment). Usual care data were obtained from ReCORD-FL, a global retrospective study of patients with r/r FL, who met similar eligibility criteria to ELARA. With a data cutoff date of 31 December 2020, 187 patients with ≥2 preceding treatment lines were included in the ReCORD-FL (median follow-up: 57 months from third-line) study. An indirect treatment comparison was performed for 97 patients from the ELARA trial and 143 patients from the ReCORD-FL study with no missing data on baseline factors. The line of therapy for which outcomes were assessed was selected or matched between cohorts using propensity score modeling. After baseline factor adjustment via weighting by odds, complete response rate (CRR; 95% confidence interval) was 69.1% (59.8%-78.3%) for tisa-cel vs. 37.3% (26.4%-48.3%) for usual care; overall response rate was 85.6% (78.7%-92.5%) vs. 63.6% (52.5%-74.7%). Kaplan-Meier probability of being progression/event-free at 12 months was 70.5% (61.4%-79.7%) for tisa-cel vs. 51.9% (40.6%-63.3%) for usual care, with hazard ratio (HR)=0.60 (0.34-0.86); 12-month overall survival was 96.6% (92.9%-100%) vs. 71.7% (61.2%-82.2%), with HR=0.2 (0.02-0.38). In conclusion, tisa-cel was associated with a 1.9-fold higher complete response rate and a 1.4-fold higher rate of being progression or event free at 12 months vs usual care, as well as a death risk reduction of 80%. The findings provide additional evidence on the benefit of tisa-cel in patients with r/r FL after ≥2 treatment lines. This trial was registered at www.clinicaltrials.gov as NCT03568461
Simulation Optimization Gantry Call-Back Control Method for Proton Therapy Systems
Wang, Feifan , Huang, Yu-Li , Ju, Feng , Wang, Feifan

Mayo Clinic

IEEE Transactions on Automation Science and Engineering | August 15, 2022 | Volume: 20 | Issue: 3 | Pages: 1565-1576

10.1109/tase.2022.3198106 Get It

Total shoulder arthroplasty versus reverse total shoulder arthroplasty: Outcome comparison in osteoarthritis patients with or without concurrent rotator cuff deficiency
Huang, Tony Chieh‐Ting , Yu, Hanzhong, Wang, Yicun , Wang, Daping , Long, Zeling , Long, Zeling , Liu, Haifeng

Mayo Clinic

Medicine | August 12, 2022 | Volume: 101 | Issue: 32 | Pages: e29896

10.1097/md.0000000000029896 | PMID 35960077 Get It

Osteoarthritis (OA) is a common shoulder disorder that impacts shoulder functions. Shoulder arthroplasty is often required to restore function and quality of life. Reverse total shoulder arthroplasty (RSA), which was originally designed mainly for irreparable rotator cuff damage, has gained popularity in recent years for the treatment of advanced shoulder OA instead of the clinically standard total shoulder arthroplasty (TSA). However, this RSA has some nonnegligible flaws such as higher complications rate and economic cost, not mention the following problems caused by irreversible physical structural damage. Therefore, the employment of RSA needs to be carefully considered. This study aimed to compare TSA and RSA in OA patients with or without rotator cuff damage to better guide clinical decision making. We believe the radical use of RSA in patients without rotator cuff deficiency may cause more harm than good. We queried the Nationwide Inpatient Sample (NIS) database from 2011 to 2014 to collect information on OA patients who received TSA and RSA. Patients were divided into 2 groups of comparison according to the presence of rotator cuff deficiency and matched with propensity score analysis. A total of 57,156 shoulder arthroplasties were identified. RSA patients in the rotator cuff deficiency group had significant higher transfusion rates and longer hospital stays. RSA patients without rotator cuff deficiency had a statistically significantly higher number of implant-related mechanical complications, acute upper respiratory infections and postoperative pain. Overall, RSA incurred higher costs in both groups. For OA patients with rotator cuff deficiencies, RSA has its benefits as complication rates were comparable to TSA. For those patients without rotator cuff deficiencies, the use of RSA should be reconsidered as there were more complications with higher severity.
Indications for Left Atrial Appendage Occlusion in the United States and Associated In-Hospital Outcomes: Results From the NCDR LAAO Registry
Daimee, Usama A. , Wang, Yongfei , Masoudi, Frederick A. , Varosy, Paul D. , Du, Chengan, Koutras, Cristina, Saw, Jacqueline , Price, Matthew J. , Curtis, Jeptha P. , Reddy, Vivek Y , Saw, Jacqueline , Price, Matthew J , Kusumoto, Fred M , Curtis, Jeptha P , Freeman, James V , Friedman, Daniel J , Reddy, Vivek Y. , Kusumoto, Fred , Freeman, James V.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | August 12, 2022 | Volume: 15 | Issue: 8 | Pages: No page available

10.1161/circoutcomes.121.008418 | PMID 35959677 Get It

Background: The Food and Drug Administration approved left atrial appendage occlusion with the Watchman device for patients who are at increased stroke risk and are suitable for oral anticoagulation but who have an appropriate reason to seek a nondrug alternative. These broad criteria raise the question of their interpretation in clinical practice. There is a lack of studies comprehensively evaluating the indications for Watchman implantation among a large series of patients from contemporary, real-world practice in the United States. Methods: We used the National Cardiovascular Data Registry Left Atrial Appendage Occlusion Registry to identify Watchman procedures performed between 2016 and 2018. We assessed procedural indications for Watchman implantation in the United States and evaluated the association between procedural indications and in-hospital adverse events. Results: A total of 38 314 procedures were included. The mean patient age was 76.1±8.1 years, and 58.9% were men. The mean CHA 2 DS 2 -VASc score was 4.8±1.5, whereas the mean hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol (HAS-BLED) score was 3.0±1.1. Prior stroke or transient ischemic attack was reported in 40.2% and prior bleeding in 70.1%, with gastrointestinal bleeding being most common (41.9%). The most common site-reported procedural indications for Watchman implantation were increased thromboembolic risk (64.8%) and history of major bleed (64.3%), followed by high fall risk (35.5%). Most (71.9%) had ≥2 procedural indications. Patients with high fall risk had increased risk of in-hospital adverse events (adjusted OR, 1.12; P =0.025), but no other differences were found in the risk of in-hospital adverse events by procedural indication. Conclusions: Among patients in the National Cardiovascular Data Registry Left Atrial Appendage Occlusion Registry, the most common procedural indications for Watchman implantation were increased thromboembolic risk, history of major bleed, and high fall risk. A majority of patients had multiple procedural indications. High fall risk conferred a modestly increased risk of in-hospital adverse events.
Bayesian sparse modeling to identify high‐risk subgroups in meta‐analysis of safety data
Qi, Xinyue , Wang, Yucai , Peterson, Christine B. , Zhou, Shouhao , Wang, Yucai , Peterson, Christine , Zhou, Shouhao

Mayo Clinic

Research Synthesis Methods | August 11, 2022 | Volume: 13 | Issue: 6 | Pages: 807-820

10.1002/jrsm.1597 | PMID 36054779 Get It

AbstractMeta‐analysis allows researchers to combine evidence from multiple studies, making it a powerful tool for synthesizing information on the safety profiles of new medical interventions. There is a critical need to identify subgroups at high risk of experiencing treatment‐related toxicities. However, this remains quite challenging from a statistical perspective as there are a variety of clinical risk factors that may be relevant for different types of adverse events, and adverse events of interest may be rare or incompletely reported. We frame this challenge as a variable selection problem and propose a Bayesian hierarchical model which incorporates a horseshoe prior on the interaction terms to identify high‐risk groups. Our proposed model is motivated by a meta‐analysis of adverse events in cancer immunotherapy, and our results uncover key factors driving the risk of specific types of treatment‐related adverse events.
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Haddad, Robert I. , Bischoff, Lindsay , Ball, Douglas W., Bernet, Victor , Blomain, Erik , Busaidy, Naifa L. , Campbell, Michael J. , Dickson, Paxton V. , Ehya, Hormoz, Guo, Theresa , Holt, Shelby , Hunt, Jason P. , Kandeel, Fouad , Lamonica, Dominick , Mandel, Susan J., McIver, Bryan, Raeburn, Christopher D., Rezaee, Rod , Roth, Mara Y. , Scheri, Randall P., Sipos, Jennifer A. , Wang, Thomas N., Wirth, Lori J. , Cassara, Carly J., Darlow, Susan, Haddad, Robert , Duh, Quan‐Yang , Goldner, Whitney Sears , Haymart, Megan R. , Iagaru, Andrei H. , Markovina, Stephanie T. , Ridge, John Andrew , Shah, Jatin P. , Sippel, Rebecca S. , Sturgeon, Cord , Wong, Richard J. , Yeh, Michael W.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 10, 2022 | Volume: 20 | Issue: 8 | Pages: 925-951

10.6004/jnccn.2022.0040 | PMID 35948029 Get It

Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation (iodine-131) in select patients and thyroxine therapy in most patients. Surgery is also the main treatment for medullary thyroid carcinoma, and kinase inhibitors may be appropriate for select patients with recurrent or persistent disease that is not resectable. Anaplastic thyroid carcinoma is almost uniformly lethal, and iodine-131 imaging and radioactive iodine cannot be used. When systemic therapy is indicated, targeted therapy options are preferred. This article describes NCCN recommendations regarding management of medullary thyroid carcinoma and anaplastic thyroid carcinoma, and surgical management of differentiated thyroid carcinoma (papillary, follicular, Hürthle cell carcinoma).
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial
Bauer, Sebastian , Jones, Robin L. , Blay, Jean‐Yves , Gelderblom, Hans , George, Suzanne , Schöffski, Patrick , Mehren, Margaret von , Kang, Yoon‐Koo , Razak, Albiruni Abdul , Attia, Steven , Cesne, Axel Le , Su, Ying , Meade, Julie, Wang, Tao , Sherman, Matthew L. , Ruiz‐Soto, Rodrigo , von Mehren, Margaret , Kang, Yoon-Koo , Trent, Jonathan , Attia, Steven , Le Cesne, Axel , Su, Ying , Ruiz-Soto, Rodrigo , Heinrich, Michael C , Blay, Jean-Yves , Jones, Robin L , Gelderblom, Hans , George, Suzanne , Bauer, Sebastian , Zalcberg, John , Trent, Jonathan C. , Heinrich, Michael C.

Mayo Clinic

Journal of Clinical Oncology | August 10, 2022 | Volume: 40 | Issue: 34 | Pages: 3918-3928

10.1200/jco.22.00294 | PMID 35947817 Get It

PURPOSE Sunitinib, a multitargeted tyrosine kinase inhibitor (TKI), is approved for advanced gastrointestinal stromal tumor (GIST) after imatinib failure. Ripretinib is a switch-control TKI approved for advanced GIST after prior treatment with three or more TKIs, including imatinib. We compared efficacy and safety of ripretinib versus sunitinib in patients with advanced GIST who were previously treated with imatinib (INTRIGUE, ClinicalTrials.gov identifier: NCT03673501 ). PATIENTS AND METHODS Random assignment was 1:1 to once-daily ripretinib 150 mg or once-daily sunitinib 50 mg (4 weeks on/2 weeks off) and stratified by KIT/ platelet-derived growth factor α mutation and imatinib intolerance. The primary end point was progression-free survival (PFS) by independent radiologic review using modified Response Evaluation Criteria in Solid Tumors version 1.1. Secondary end points included objective response rate by independent radiologic review, safety, and patient-reported outcome measures. RESULTS Overall, 453 patients were randomly assigned to ripretinib (intention-to-treat [ITT], n = 226; KIT exon 11 ITT, n = 163) or sunitinib (ITT, n = 227; KIT exon 11 ITT, n = 164). Median PFS for ripretinib and sunitinib ( KIT exon 11 ITT) was 8.3 and 7.0 months, respectively (hazard ratio, 0.88; 95% CI, 0.66 to 1.16; P = .36); median PFS (ITT) was 8.0 and 8.3 months, respectively (hazard ratio, 1.05; 95% CI, 0.82 to 1.33; nominal P = .72). Neither was statistically significant. Objective response rate was higher for ripretinib versus sunitinib in the KIT exon 11 ITT population (23.9% v 14.6%, nominal P = .03). Ripretinib was associated with a more favorable safety profile, fewer grade 3/4 treatment-emergent adverse events (41.3% v 65.6%, nominal P < .0001), and better scores on patient-reported outcome measures of tolerability. CONCLUSION Ripretinib was not superior to sunitinib in terms of PFS. However, meaningful clinical activity, fewer grade 3/4 treatment-emergent adverse events, and improved tolerability were observed with ripretinib.
Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma
Bewicke‐Copley, Findlay , Korfi, Koorosh , Araf, Shamzah, Hodkinson, Brendan P. , Kumar, Emil , Cummin, Thomas , Ashton‐Key, Margaret , Barrans, Sharon, Hoppe, Suzan van, Burton, Cathy , Elshiekh, Mohamed , Rule, Simon , Crosbie, Nicola, Clear, Andrew , Calaminici, Maria , Runge, Hendrik F.P. , Hills, Robert K. , Sha, Chulin , Painter, Daniel , Smith, Alexandra , Naresh, Kikkeri N. , Westhead, David R. , Steele, Andrew J. , Hodson, Daniel J. , Balasubramanian, Sriram , Runge, Hendrik , Scott, David W , Nagano, Ai , Davies, Andrew , Painter, Daniel , Smith, Alexandra , Gribben, John G. , Westhead, David R , Okosun, Jessica , Steele, Andrew , Hodson, Daniel J , Johnson, Peter , Wang, Jun , Fitzgibbon, Jude , Naresh, Kikkeri N , Scott, David W. , Rimsza, Lisa M. , Menon, Geetha, Davies, John R., Davies, Andrew , Johnson, Peter , Fitzgibbon, Jude

Mayo Clinic

Blood Advances | August 10, 2022 | Volume: 7 | Issue: 5 | Pages: 845-855

10.1182/bloodadvances.2022007536 | PMID 35947123 Get It

Abstract Despite the effectiveness of immuno-chemotherapy, 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience relapse or refractory disease. Longitudinal studies have previously focused on the mutational landscape of relapse but fell short of providing a consistent relapse-specific genetic signature. In our study, we have focused attention on the changes in GEP accompanying DLBCL relapse using archival paired diagnostic/relapse specimens from 38 de novo patients with DLBCL. COO remained stable from diagnosis to relapse in 80% of patients, with only a single patient showing COO switching from activated B-cell–like (ABC) to germinal center B-cell–like (GCB). Analysis of the transcriptomic changes that occur following relapse suggest ABC and GCB relapses are mediated via different mechanisms. We developed a 30-gene discriminator for ABC–DLBCLs derived from relapse-associated genes that defined clinically distinct high- and low-risk subgroups in ABC–DLBCLs at diagnosis in datasets comprising both population-based and clinical trial cohorts. This signature also identified a population of &lt;60-year–old patients with superior PFS and OS treated with ibrutinib–R-CHOP as part of the PHOENIX trial. Altogether this new signature adds to the existing toolkit of putative genetic predictors now available in DLBCL that can be readily assessed as part of prospective clinical trials.
Risk of Dementia Associated With Atrial Cardiopathy: The ARIC Study
Johansen, Michelle C. , Wang, Wendy , Zhang, Michael J. , Knopman, David S. , Ndumele, Chiadi E. , Mosley, Thomas H. , Selvin, Elizabeth , Shah, Amil M. , Solomon, Scott D. , Selvin, Elizabeth , Mosley, Thomas H. , Knopman, David S. , Zhang, Michael , Ndumele, Chiadi , Gottesman, Rebecca F , Chen, Lin Y , Selvin, Elizabeth , Johansen, Michelle C , Shah, Amil , Solomon, Scott David , Gottesman, Rebecca F. , Chen, Lin Y.

Mayo Clinic

Journal of the American Heart Association | August 10, 2022 | Volume: 11 | Issue: 16 | Pages: No page available

10.1161/jaha.121.025646 | PMID 35946474 Get It

Background The contribution of atrial cardiopathy to dementia risk is uncharacterized. We aimed to evaluate the association of atrial cardiopathy with incident dementia and potential mediation by atrial fibrillation (AF) and stroke. Methods and Results We conducted a prospective cohort analysis of participants in the ARIC (Atherosclerosis Risk in Communities) study attending visit 5 (2011–2013). We used Cox regression to determine the association between atrial cardiopathy and risk of dementia. Structural equation modeling methods were used to determine potential mediation by AF and/or stroke. Atrial cardiopathy was defined if ≥1 of the following at visit 5: P‐wave terminal force >5000 mV·ms in ECG lead V1, NT‐proBNP (N‐terminal pro–brain natriuretic peptide) >250 pg/mL or left atrial volume index ≥34 mL/m 2 by transthoracic echocardiography. We repeated our analysis necessitating ≥2 markers to define atrial cardiopathy. The prevalence of atrial cardiopathy was 34% in the 5078 participants (mean age 75 years, 59% female, 21% Black adults), with 763 participants developing dementia. Atrial cardiopathy was significantly associated with dementia (adjusted HR, 1.35 [95% CI, 1.16–1.58]), with strengthening of the effect estimate when necessitating ≥2 biomarkers (adjusted HR, 1.54 [95% CI, 1.25–1.89]). There was an increased risk of dementia among those with atrial cardiopathy when excluding those with AF (adjusted HR, 1.31 [95% CI, 1.12–1.55]) or stroke (adjusted HR, 1.28 [95% CI, 1.09–1.52]). The proportion of the effect mediated by AF was 4% ( P =0.005), and 9% was mediated by stroke ( P =0.048). Conclusions Atrial cardiopathy was significantly associated with an increased risk of dementia, with only a small percent mediation of the effect by AF or stroke.
Young serum protects against memory impairment in APP/PS1 transgenic mice by blocking neutrophil infiltration
Guo, Kaihua , Qi, Fangfang , Zuo, Zejie , Wu, Tong , Liu, Hao , Tang, Jiaoling , Wang, Qingbo , Xie, Yufeng , Tan, Liren, Yang, Yunjie , Zhang, Xiaoran , Xu, Jie , Yao, Zhibin , Wang, Shengwen , Qi, Fangfang , Hu, Kaishun , Wang, Rui Ting , Wu, Long‐Jun

Mayo Clinic

No container title available | August 9, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1906482/v1 Get It

Abstract Activation of innate immunity in the brain is a prominent feature of Alzheimer's disease (AD). The present study investigated the regulation of innate immunity by young serum in a transgenic AD mouse model. We found that young serum significantly reduced the number of neutrophils and microglial reactivity in the brains of APP/PS1 mice. Neutrophil depletion via Ly6G neutralizing antibodies mimicked the benefits of young serum on AD brain functions. Serum proteomic analysis of young serum revealed significant enrichment of the factors VEGF-A and CXCL1, which are crucial for neutrophil migration and chemotaxis, leukocyte migration, and cell chemotaxis. Intravenously injected VEGF-A reversed Aβ-induced decreases in Cdk5 and increases in CXCL1 in vitro and blocked neutrophil infiltration into the AD brain. Endothelial Cdk5 overexpression conferred an inhibitory effect on CXCL1 and neutrophil infiltration and thereby restored memory in APP/PS1 mice. Our data uncover a previously unknown link between blood-derived VEGF signaling and neutrophil infiltration and provide a rationale for targeting endothelial Cdk5 signaling as a potential therapeutic strategy for AD.